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that a limited number of mammalian microRNAs also display antiviral effects. This article summa-
rizes the data in the ﬁeld paying a special attention to the conservation of the microRNA target
sequences in the viral populations. This issue is relevant both for the evaluation of the biological sig-
niﬁcance of the antiviral effects and for the development of microRNA-based strategies for antiviral
intervention.
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MicroRNAs (miRNAs) are small non-coding RNAs that modulate
gene expression at post-transcriptional level by targeting mRNAs
for degradation or by inhibiting translation [1]. At the time of writ-
ing, the miRNA database (http://www.mirbase.org) [2] contained
1100 human miRNAs which may regulate up to 30% of the pro-
tein-coding genes [3]. MicroRNAs have been shown to play a pre-
valent role in development and cell differentiation, maintenance
of stem cell character, and apoptosis [4,5]. Moreover, several stud-
ies indicate that miRNA genes may act as oncogenes or tumor sup-
pressors [6,7].
MicroRNAs are generally transcribed by RNA polymerase II as
long precursors, pri-miRNAs, which are processed in the nucleus
to 70 nt hairpin structures by the enzyme Drosha. These prod-
ucts, pre-miRNAs, are then transported to the cytoplasm and
processed into 22 nt miRNA duplexes by the action of the mul-
ti-domain RNase III-like enzyme Dicer [8]. Each miRNA duplex is
then unwound and the strand with the lower stability in the 50
end (guide strand) is preferentially selected [9] and incorporated
into a large, dynamic multi-protein complex called RNA-induced
silencing complex (RISC). The targets of miRNA-loaded RISC are
mRNAs presenting a near-perfect sequence complementarity with
nucleotides 2–7 in the 50 portion of the miRNA (the so-called seed
region), and additional base pairings with its 30 region. RISCalf of the Federation of European B
.mediates down-regulation of target gene expression by cleavage
or translational inhibition of the target mRNA. The choice between
these two modes of action is dictated by the degree of complemen-
tarity between miRNA and its target. Near-perfect complementar-
ity produces cleavage of the mRNA, followed by its complete
degradation, whereas partial complementarity causes translational
inhibition [10]. In animals, endonucleolytic cleavage is rare. Most
of the times, miRNA binding to mRNA leads to inhibition of trans-
lation or mRNA de-adenylation and subsequent exonucleolytic
cleavage [11].
RNA-mediated post-transcriptional gene silencing can also be
triggered by exogenous dsRNA molecules. In plants and inverte-
brates, viral dsRNA molecules are processed into small interfering
RNAs (siRNAs) by Dicer and are incorporated into RISC to target
pathogen’s genome and mRNAs for cleavage [12,13]. Although
undisputed in plants and invertebrates, a defensive role for RNA
silencing in vertebrates has not been sufﬁciently deﬁned. In verte-
brates, cell exposure to long dsRNA triggers the interferon response
as primary form of innate antiviral defense. This leads to a global
shutdown in protein translation, cellular RNA degradation and of-
ten the death of virus-infected cells [14]. Nevertheless, recent data
provide increasing evidence that vertebrate miRNAs can directly
affect viral gene expression.
2. Primate foamy virus type 1
Primate foamy virus type 1 (PFV-1) is a retrovirus causing per-
sistent infections in non-human primates. PFV-1 can sporadicallyiochemical Societies. Open access under CC BY-NC-ND license.
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atic. In 2005 Lecellier et al. found that the human miRNA hsa-miR-
32 can target the open reading frame 2 of PFV-1, shared by Bet and
EnvBet proteins (Fig. 1), thus inhibiting viral translation and reduc-
ing the accumulation of the retrovirus in cultured Hela and BHK21
cells [15,16]. In the same study, Tas protein of PFV-1 was shown to
suppress microRNA-mediated functions in mammalian cells, coun-
teracting the effect of hsa-miR-32. These results indicated that RNA
silencing limits the replication of PFV-1 and that miR-32 contribute
substantially to this effect. Overall this work represented the ﬁrst
report of a human miRNA with a direct antiviral effect. It will also
be interesting to test the expression level of miR-32 in salivary
glands, where PFV normally establishes infection.
3. Hepatitis C virus
Hepatitis C virus (HCV) is a member of the Flaviviridiae family
with a single-stranded RNA genome of positive polarity, whose
replication is assisted by a virally encoded RNA-dependent RNAFig. 1. Human microRNAs with antiviral effects.polymerase. HCV infection is one of the major causes of chronic li-
ver disease, including cirrhosis and liver cancer. In 2007 Pedersen
et al. found that interferon b upregulates cellular expression of
hsa-miR-196 and hsa-miR-448 and that these miRNAs inhibit
HCV replication in cultured hepatic cells [17]. MiR-196 was shown
to target the non-structural protein 5A (NS5A) coding sequence
whereas miR-448 had its target site in the Core protein ORF
(Fig. 1). Transfection of synthetic mimics of miR-196 and miR-
448 reproduced the effect of interferon b on HCV replication
whereas their neutralization by miRNA-inhibitors reduced the
antiviral effect of interferon against HCV. The anti-HCV activity of
miR-196 was later conﬁrmed by Hou et al. [18] that showed a
marked repression of HCV RNA and protein expression in cultured
cells treated with the miR-196 mimic. Finally, another study
showed that cellular miR-199a-3p can target the 50-UTR of HCV
genomic RNA, thereby inhibiting viral replication in cultured cells
[19].
Overall, these data indicate that three microRNAs expressed in
human liver can counteract HCV replication, with two of themThe miRNA seed sequences are underlined.
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ent study has shown that hsa-miR-122 has an opposite effect on
HCV replication. This microRNA is highly expressed in human liver
and interacts with the 50-UTR of HCV genome resulting in up-
regulation of viral RNA levels [20]. The mechanism of action of this
miRNA has been inquired extensively and reviewed elsewhere
[21–23].4. Human immunodeﬁciency virus type 1
Human immunodeﬁciency virus type 1 (HIV-1) is a retrovirus
causing acquired immunodeﬁciency syndrome (AIDS), a progres-
sive failure of the immune system leading to life-threatening
opportunistic infections and cancers [24]. HIV-1 mainly infects
CD4+ T cells, macrophages and dendritic cells. In 2007 Zhang
et al. showed that human microRNAs miR-28, miR-125b, miR-
150, miR-223, and miR-382 are overexpressed in resting CD4+
T cells and are able to target the 30 end of human HIV-1 RNA,
thus silencing almost all viral messengers [25] (Fig. 1). Speciﬁc
inhibitors of these cellular miRNAs reversed their effects, mea-
sured either as HIV-1 translation or HIV-1 virus production.
These data strongly argued for a role of these cellular miRNAs
in counteracting viral replication and contributing to HIV la-
tency. Later, Ahluwalia et al. showed that human microRNA
hsa-miR-29a interferes with viral nef protein expression and
HIV-1 replication [26] (Fig. 1). The same microRNA was later
found to possess a target site in the 30-UTR of HIV-1. Inhibiting
miR-29a enhanced HIV-1 viral production and infectivity,
whereas ectopic expression of a miR-29a mimic suppressed viral
replication [27]. These data clearly indicate that several cellular
microRNAs can target directly HIV-1 gene expression thereby
repressing viral replication. To counteract this cellular defense,
HIV-1 has evolved in its Tat protein a suppressor of RNA silenc-
ing function. Tat abrogates the cellular RNA-silencing defense by
subverting the ability of Dicer to process precursor double-
stranded RNAs [28–31]. Also HIV-1 TAR RNA can attenuate
RNA-silencing in human cells; it binds to cellular TRBP, an essen-
tial partner for Dicer and RISC function [32]. Other viruses, such
as Ebola virus and inﬂuenza A virus, encode RNA silencing sup-
pressors that are functionally equivalent to HIV-1 Tat [33,34].
Interestingly, there are some data suggesting that cellular
microRNAs may counteract inﬂuenza A virus infection [35].5. Human papillomavirus
Human papillomavirus (HPV) is a sexually transmitted dou-
ble-stranded DNA virus whose infection is a cause of cervical
intraepithelial neoplasia and cancer. Very recently, Nuovo et al.
have shown that hsa-miR-125b may target HPV replication
[36]. In situ analysis of human cervical tissue showed a dramatic
reduction in hsa-miR-125b expression in the koilocytes, the
cytologic marker of productive HPV infection, whereas the
expression of the miR-125b precursor was unaffected. Later,
cotransfection of NIH 3T3 ﬁbroblasts with HPV genome and
hsa-miR-125b mimic or anti-sense inhibitor showed a reduction
or increase of viral DNA synthesis, respectively. Sequence analy-
sis of the viral genome revealed a putative binding site for hsa-
miR-125b within the coding sequence of L2 capsid protein
(Fig. 1). Finally, transfection of HPV L2 ORF in NIH 3T3 cells re-
sulted in a marked reduction in miR-125b levels. Taken together,
these data suggest that hsa-miR-125b may be able to counteract
HPV replication and that the virus induces the inactivation of
miR-125b. However these conclusions will need to be supported
by more direct studies on the human cells naturally infected by
HPV.6. Human hepatitis B virus
Human hepatitis B virus (HBV) is a widely spread hepatotropic
virus that causes persistent infections [37]. HBV is characterized by
a circular DNA genome of 3.2 kb which is only partially double-
stranded [38]. This is replicated through an RNA intermediate,
the pregenomic RNA, which is produced by transcription of the en-
tire viral DNA by cellular RNA polymerase. Pregenomic RNA is then
converted into the viral DNA genome by the HBV polymerase, a
multifunctional enzyme with reverse transcriptase, DNA-depen-
dent DNA polymerase, and RNase H activities [39]. The analysis
of the hepatitis B virus (HBV) genome by the computer program
MiRanda led to the identiﬁcation of seven sites that are potential
targets for human liver microRNAs. These sites were found to be
clustered in a 995 bp segment within the viral polymerase ORF
and the overlapping surface antigen ORF, and conserved among
the most common HBV subtypes. The HBV genomic targets were
then subjected to a validation test based on cultured hepatic cells
(HepG2, HuH-7, and PLC/PRF/5) and luciferase reporter genes. In
this test, one of the selected microRNAs, hsa-miR-125a-5p
(Fig. 1), was found to interact with the viral sequence and to sup-
press the reporter activity markedly. The microRNA was then
shown to interfere with the viral translation, down-regulating
the expression of the surface antigen [40].
Another study has shown that two other human microRNAs
targeting the overlapping surface antigen and polymerase ORFs,
hsa-miR-199a-3p and hsa-miR-210, are also able to suppress
HBV replication in cultured hepatic cells [41] (Fig. 1).7. Conservation of the microRNA target sequences
Most of the results described above have been obtained in vitro,
studying viral replication in cultured mammalian cells. On the
other hand there are studies showing that cellular microRNAs
can affect viral replication in vivo. One investigation on vesicular
stomatitis virus (VSV) infection in mice showed that miR-24 and
miR-93 can target viral large protein and phosphoprotein genes
and that lack of these miRNAs leads to hypersusceptibility to VSV
infection [42]. Another study has conﬁrmed the positive effect of
hsa-miR-122 on HCV replication: treatment of chronically infected
chimpanzees with a locked nucleic acid-modiﬁed antisense inhib-
itor of miR-122 leads to long-lasting suppression of HCV viremia
[43]. These results support the emerging concept that some mam-
malian microRNAs can directly affect viral gene expression by
interacting with viral mRNAs or RNA genomes [44]. This is also
supported by computational studies showing that human miRNAs
preferentially target the genomes of human-infecting viruses com-
pared to invertebrate viruses [45], whereas plant miRNAs target
plant viruses more efﬁciently than the genomes of animal-
infecting viruses [46]. Finally, it is known that several miRNA tar-
get sequences are well conserved in viral genomes. To gain further
insights into this aspect of microRNA biology, we consulted nucle-
otide databases at National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov). This search revealed that several
thousands sequences have been deposited for each of the patho-
genic viruses considered in this article. The total number of entries
was 35758 for HBV, 110396 for HCV, 369985 for HIV-1 and 5577
for HPV. Sequences belonged to various viral genotypes, subtypes,
serotypes, or isolates, and most of them covered only part of the
viral genome. Selection of the entries containing the reported miR-
NA target sites, was performed by Blast search of the miRNA-pair-
ing sequences described in Fig. 1. This search yielded a total
number of targets in each viral database ranging from 1754 for
hsa-miR-210 to 22199 for hsa-miR-150 (Fig. 2). Further examina-













125a-5p 7652 4275 (56) 6465 (84) 
199a-3p 20153 2767 (14) 20105 (100) HBV 
210 1754 1 (0.06) 4 (0.2) 
196 4599 15 (0.3) 258 (6) 
199a-3p 2913 941 (32) 1440 (49) HCV 
448 2898 25 (1) 2559 (88) 
28 5568 2673 (48) 5273 (95) 
29a 22020 839 (4) 14229 (65) 
125b 20007 4405 (22) 13085 (65) 
150 22199 10823 (49) 16090 (72) 
223 13247 2250 (17) 10272 (78) 
HIV-1 
382 5241 108 (2) 4297 (82) 
HPV 125b 2751 115 (4) 962 (35) 
Fig. 2. Pathogenic viruses targeted by human microRNAs and conservation of their
target sequences. Target sequences were identiﬁed by Blast search of nucleotide
collections at NCBI using as queries the miRNA-pairing sequences reported in Fig. 1.
Search was restricted to selected viruses by using their taxonomy IDs: 10407 for
HBV, 11103 for HCV, 11676 for HIV-1, and 333750 for HPV. Target sequences were
then downloaded and examined to verify their conservation. aNumber of viral
sequences homologous to the reported microRNA target. bNumber of viral
sequences identical to the reported microRNA target. cNumber of targets showing
a seed-matching sequence identical to the reported one.
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125a are identical to the one reported [40] and 84% display an
identical seed-matching sequence (Fig. 2). Other examples of well
conserved sequences are given by the HIV-1 targets for hsa-miR-28
and 150, whose seed-matching sites are identical to the reported
ones for 95% and 78% of the entries, respectively. Finally, the
HCV target for hsa-miR-448 is also fairly conserved.
Given the high mutation rate of viral polymerases, the existence
of some well-conserved viral genomic sequences suggests that a
selective pressure may be preserving them. This may be due to
an essential role that the sequence plays for its (1) protein-coding
properties, sometimes with two overlapping open reading frames,
(2) gene expression regulatory signals, such as those that control
RNA splicing or stability, (3) RNA secondary structure, and/or (4)
ability to bind to a host miRNA (see below). In the case of HBV,
the mRNA sequence targeted by hsa-miR-125a-5p (Fig. 1) encodes
amino acid residues 244–252 of polymerase and 64–72 of surface
antigen, with the latter residues falling within the extracellular
pre-S1 domain that is responsible for receptor binding on hepato-
cytes [40].
The available data on the antiviral effects of mammalian
microRNAs collected both in vitro and in animal models, the
knowledge that some mammalian viruses encode suppressors of
RNA-induced silencing, and the theoretical considerations about
the conservation of the microRNA target sites, suggest that some
human microRNAs effectively contribute to the host defense by
targeting essential viral genes, thereby reducing the replication
efﬁciency of the virus. It can be hypothesized that this effect
accompanies the well known immune response producing an over-
all antiviral effect that in some cases would be sufﬁcient to recover
from the infection (as for many HBV-infected individuals) whereas
in many others would only counteract it, leading to a persistent
infection (the other HBV-, HCV-, HIV-1-, and HPV-infected pa-tients). The latter outcomemay also be part of the replication strat-
egy of the virus, because it leads to a long spreading ability often
lasting one or more decades. If this is the case, then the miRNAs
with antiviral effects may be considered host molecules that
viruses co-opt to suppress their own replication and to establish
a persistent infection, as already proposed [47,48]. Then the miRNA
target sequences in viral genomes would be conserved also for
their ability to make the virus sensitive to the action of host miR-
NAs. In this scenario, microRNAs with antiviral effects may be con-
sidered ﬁne regulators of virus-host coexistence, leading to
persistent infections that are beneﬁcial both for the host survival
and the viral spread.8. Concluding remarks
In our opinion, the available experimental data on the role of
microRNAs in virus–host interactions sufﬁciently prove that bind-
ing of human microRNAs to viral RNA genomes or transcripts can
occur under natural conditions. Furthermore, the knowledge that
some target sequences for binding of cellular miRNAs are well con-
served in viral genomes supports the concept that such interac-
tions have a biological signiﬁcance. However, a general
conclusion on the role of these interactions cannot be drawn yet.
One possibility is that they are beneﬁcial for the host only, with
some miRNAs being part of the host innate antiviral defense.
Otherwise, the miRNA–RNA interaction may be beneﬁcial for the
virus only, as in the case of miRNA-122 acting on HCV. Finally,
the interaction may be beneﬁcial for both the host and the virus,
as already proposed in the previous paragraph, because it possibly
leads to a persistent infection with a long host survival and a high
spread of the virus in the human population.
Independently of their biological role, human microRNAs with
antiviral effects may be exploited for the development of new
strategies for antiviral intervention. Delivery of synthetic miRNA
mimics or treatments that modulate the expression of cellular
miRNAs could in fact represent useful strategies to unbalance the
virus-host coexistence and re-direct the outcome from a persistent
infection to a complete recovery. In this regard, priority should be
given to those miRNAs whose targets are well-conserved in the vir-
al population. A key impulse in this ﬁeld may also be given by the
study of miRNA gene promoters, eventually leading to the develop-
ment of treatments that increase their activity in infected tissues.
Otherwise, the use of vectors for the ectopic expression of miRNA
mimics [49–52] directed towards conserved target sites can also be
used to boost the cellular reservoir of antiviral microRNAs.Acknowledgments
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